Last reviewed · How we verify
Shanghai Shengdi Pharmaceutical Co., Ltd — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Gadobutrol Injection | Gadobutrol Injection | phase 3 | Gadolinium-based contrast agent | Water protons (paramagnetic enhancement) | Diagnostic Imaging |
Therapeutic area mix
- Diagnostic Imaging · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Bayer · 1 shared drug class
- Bracco Diagnostics, Inc · 1 shared drug class
- GE Healthcare · 1 shared drug class
- Guerbet · 1 shared drug class
- Paracelsus Medical University · 1 shared drug class
- Seoul National University Hospital · 1 shared drug class
- The Central Hospital of Lishui City · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Shanghai Shengdi Pharmaceutical Co., Ltd:
- Shanghai Shengdi Pharmaceutical Co., Ltd pipeline updates — RSS
- Shanghai Shengdi Pharmaceutical Co., Ltd pipeline updates — Atom
- Shanghai Shengdi Pharmaceutical Co., Ltd pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Shanghai Shengdi Pharmaceutical Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shanghai-shengdi-pharmaceutical-co-ltd. Accessed 2026-05-17.